AUA 2025: What to watch for in urologic oncology

The American Urological Association (AUA) will try its luck in Las Vegas, Nevada for its 2025 annual meeting. Taking place at the Venetian Las Vegas from April 26-29 (and preceded by the AUA Innovation Nexus on April 25), the meeting will feature scientific abstracts, lectures, Crossfire Debates, the P2s: Practice-changing Paradigm-shifting Clinical Trials in Urology, and much more. In this article, we preview several noteworthy P2 presentations in the urologic oncology space. You can follow Urology Times’ coverage of the meeting here.

AUA 2025 will take place April 26-29 in Las Vegas, Nevada.

Sasanlimab in combination with Bacillus Calmette-Guerin improves event-free survival versus Bacillus Calmette-Guerin as standard of care in high-risk non-muscle-invasive bladder cancer: Neal D. Shore, MD, FACS, medical director of Carolina Urologic Research Center in Myrtle Beach, South Carolina, will be presenting these data. Previously reported data from the phase 3 CREST trial (NCT04165317) of sasanlimab found that treatment with sasanlimab/BCG was associated with clinically meaningful and statistically significant improvement in event-free survival vs BCG alone.¹

BOND-003 Cohort C- Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma In Situ: Mark D. Tyson II, MD, MPH, a urologic oncologist at the Mayo Clinic in Phoenix, Arizona, will present data from BOND-003 (NCT04452591) during the morning plenary session. Tyson previously reported on cretostimogene at the Society of Urologic Oncology 25th Annual Meeting. The overall complete response (CR) rate was 74.5% (95% CI, 65.4%-82.4%). At 12 months, the CR rate was 46% (95% CI, 36.9-56.1) and 50% (95% CI, 39.6-58.9%) by Kaplan-Meier estimate. According to the presentation, there were “25 confirmed CRs that have reached 24-month timepoint and beyond,” with a 24-month CR rate of 41% (95% CI, 30.4-50.8) by Kaplan-Meier estimate.²

TAR-200 monotherapy in patients with bacillus Calmette-Guerin–unresponsive high-risk non–muscle-invasive bladder cancer carcinoma in situ: 1-year durability and patient-reported outcome: This is first of 2 P2 presentations on TAR-200, an intravesical delivery system that works by providing sustained low doses of localized gemcitabine via insertion into the bladder. Joseph Jacob, MD, an associate professor of urology at Upstate Medical University in Syracuse, New York, will present these data.

TAR-200 monotherapy in patients with bacillus Calmette-Guerin–unresponsive papillary disease–only high-risk non–muscle-invasive bladder cancer: first results from Cohort 4 of SunRISe-1: Felix Guerrero-Ramos, MD, PhD, FEBU, attending urologist at Hospital Universitario 12 de Octubre in Madrid, Spain, will present data from cohort 4 of the SunRISe-1 trial (NCT04640623) evaluating TAR-200 in a cohort of patients with BCG-unresponsive, papillary disease only, high-risk non–muscle-invasive bladder cancer. At the Society of Urologic Oncology 25th Annual Meeting, investigators reported additional data on the safety and tolerability of TAR-200 monotherapy from cohort 2. As centrally assessed, the CR rate was 83.5% (95% CI, 73.9-90.7); the CR rate was 85.9% (95% CI, 76.6-92.5) per investigator assessment.³

Radical cystectomy versus bladder-sparing therapy for recurrent high-grade non-muscle invasive bladder cancer: Results from the Comparison of Intravesical Therapy and Surgery as Treatment: John L. Gore, MD, MS, an associate professor of urology and a professor of surgery at the University of Washington in Seattle, is the presenting author for this study.

A prospective, multi-center study assessing effectiveness, safety, and performance of the Hugo™ robotic-assisted surgery system in the US urologic population: Michael R. Abern, MD, an associate professor of urology at Duke Cancer Institute in Durham, North Carolina, is the presenting author for this study.

REFERENCES

1. Pfizer’s sasanlimab in combination with BCG improves event-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer. News release. Pfizer. January 10, 2025. Accessed April 21, 2025. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-sasanlimab-combination-bcg-improves-event-free

2. Tyson M, Uchio E, Nam J-K, et al. Topline results from BOND-003: a phase-3 study of intravesical cretostimogene grenadenorepvec for the treatment of high-risk BCG-unresponsive NMIBC with CIS. Presented at: Society of Urologic Oncology 25th Annual Meeting. December 4-6, 2024. Dallas, Texas. Late-breaking abstract

3. Daneshmand S, Zainfeld D, Pieczonka C, et al. Safety and tolerability of TAR-200 monotherapy in patients with bacillus Calmette–Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) in SunRISe-1. Presented at: Society of Urologic Oncology 25th Annual Meeting. December 4-6, 2024. Dallas, Texas. Abstract 135. Accessed April 21, 2025. https://suo-abstracts.secure-platform.com/a/gallery/rounds/21/details/3800